CliffBio
biologic

Tepezza

teprotumumab-trbw

Loss of exclusivityJanuary 2032projected — 12-year biologic exclusivity estimate
CompanyHorizon Therapeutics Ireland DAC

Drug detail

Brand nameTepezza
Active ingredientteprotumumab-trbw
Strength500MG
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalJanuary 2020
Marketing statusRx

More from Horizon Therapeutics Ireland DAC

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Tepezza patent cliff — loss of exclusivity January 2032 | CliffBio